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Abstract
Background: Antinuclear antibody (ANA) tests are frequently used to screen children for chronic
inflammatory diseases such as systemic lupus erythematosus (SLE). However, the diagnostic utility
of this test is limited because of the large number of healthy children who have low-titer positive
tests. We sought to determine the clinical utility of ANA tests in screening children for rheumatic
disease and to determine whether there are specific signs or symptoms that enhance the clinical
utility of ANA tests in children.
Methods: We undertook a retrospective analysis of 509 new patient referrals. Charts of patients
referred because of results of ANA testing were selected for further analysis. Children with JRA,
SLE, and other conditions were compared using demographic data, chief complaints at the time of
presentation, and ANA titers.
Results: One hundred ten patients were referred because of an ANA test interpreted as positive.
Ten patients were subsequently diagnosed with SLE. In addition, we identified one patient with
mixed connective tissue disease, and an additional child with idiopathic Raynaud's phenomenon.
Eighteen children of the children referred for a positive ANA test had juvenile rheumatoid arthritis
(JRA). Another 80 children with positive ANA tests were identified, the majority of whom (n = 39,
49%) had musculoskeletal pain syndromes. Neither the presence nor the titer of ANA served to
distinguish children with JRA from children with other musculoskeletal conditions. Children with
JRA were readily identified on the basis of the history and physical examination. Children with SLE
were therefore compared with children with positive ANA tests who did not have JRA, designated
the "comparison group." Non-urticarial rash was more common in children with SLE than in
children without chronic inflammatory disease (p = 0.007). Children with SLE were also older
(mean ± sd = 14.2 ± 2.5 years) than the comparison group (11.0 ± 3.6 years; p = 0.001). ANA titer
was also a significant discriminator between children with SLE and children without chronic
inflammatory disease. The median ANA titer in children with SLE was 1: 1,080 compared with
1:160 for other children (p < 0.0001). ANA titers of ≥1,080 had a positive predictive value for SLE
of 1.0 while titers of ≤1: 360 had a negative predictive value for lupus of 0.84.
Conclusion: Age and ANA titer assist in discriminating children with SLE from children with other
conditions. ANA tests are of no diagnostic utility in either making or excluding the diagnosis of JRA.
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Background
Systemic lupus erythematosus (SLE) is a chronic, multi-
system disease characterized by inflammation in multiple
organs, including kidney, heart, lung, and brain [1].
Although generally considered rare in children, as many
as 15–17% of cases will present in childhood [2]. Because
of its protean manifestations [3], SLE is frequently consid-
ered in the differential diagnosis of children presenting
with otherwise common childhood symptoms, such as
fatigue or arthralgia. Distinguishing children with SLE
from children with mild or self-limited disease is compli-
cated by the fact that the primary screening test for SLE,
antinuclear antibody (ANA) assays, is commonly positive
in healthy children [4,5]. Indeed, Malleson and colleagues
[6] have shown that ANA tests may be positive in as many
as 33% of healthy children. Thus, the practitioner may be
thwarted in attempts to exclude the diagnosis of SLE in the
face of low-titer positive tests.
We have recently reviewed our experience with juvenile
rheumatoid arthritis (JRA), attempting to identify chil-
dren with JRA based on the specific complaints with
which they were referred for rheumatology consultation
[7]. Children with JRA presented with symptoms of gait
disturbance and joint swelling that facilitated their dis-
tinction from other children presenting with muscu-
loskeletal complaints. Musculoskeletal pain was
conspicuously absent as a presenting complaint in chil-
dren with JRA.
These considerations notwithstanding, ANA tests con-
tinue to be used as a screening test for rheumatic disease
in children. We therefore attempted to determine whether
there are specific aspects of the history and physical exam-
ination that may assist the practitioner is determining
whether an ANA test interpreted as "positive" by a clinical
laboratory is diagnostically significant in a child.
Methods
Patients and patient records
Charts of all children seen for initial pediatric rheumatol-
ogy consultation at the Children's Hospital of Oklahoma
rheumatology clinic between April 1, 1998 and August 1,
2002 were reviewed. From these records, we selected all
children 18 years of age or younger whose reason for refer-
ral included a positive ANA test. Records of children pre-
viously seen by another rheumatologist (e.g., for follow-
up of a previously-diagnosed condition) were excluded.
Patient records from these dates all document chief com-
plaints articulated by the patient (or parent) as described
by Weed [8,9]. Where necessary (e.g., where there were
inadequate records or the patient was unclear of why they
were sent to a specialist), identification of the problem for
which the patient was referred was affirmed or clarified by
contacting the referring physician at the time of consulta-
tion. In addition, charts were reviewed for demographic
information that included: the patient's age, sex, duration
of symptoms, and ultimate diagnosis. Results of complete
blood counts (CBC) and differentials were also reviewed.
The diagnosis of SLE was made based on the 1982 ACR
criteria [10]. The diagnosis of JRA was made based on
standard criteria [11]. Non-inflammatory forms of musc-
uloskeletal pain, overuse syndromes, and mechanical
forms of musculoskeletal pain were diagnosed based on
history, physical findings, and, where appropriate, labora-
tory and/or radiographic findings as described by Sherry
and Malleson [12]. Viral arthritis was diagnosed in chil-
dren with transient synovitis that resolved spontaneously
within 2 months of onset and did not subsequently recur.
Laboratory values
ANA titers as obtained and recorded by the primary care
physician were used as the basis of comparing children
with SLE to children with other diagnoses.
Statistical analysis
Results were entered into a computer database and trans-
ferred to a commercially-available statistical software
package (GraphPad Prism, San Diego, CA). Comparisons
between groups (SLE vs. others) were undertaken using 2-
tailed independent t-tests. Non-continuous variables and
variables with non-parametric distribution were analyzed
using the Mann-Whitney U test using the same statistical
software. Proportions of different patients in specific sub-
groups were analyzed from contingency tables using
Fisher's exact test. Statistical significance was assumed for
p-values ≤0.05.
The positive or negative predictive values for specific ANA
titers or specific ages was determined using conventional
methods as follows:
Results
Records of 509 children were reviewed. Of these, 10 chil-
dren were diagnosed as having SLE. In addition, one child
each was diagnosed with mixed connective tissue disease
and with Raynaud's phenomenon. The latter was fol-
lowed for 18 months without any signs of systemic dis-
ease developing. For purposes of this paper, the children
with Raynaud's phenomenon and mixed connective tis-
sue disease were excluded from further analysis, as their
numbers are too small for statistical comparison. In
another 108 cases, a positive ANA test was indicated as a
Positive predictive value  =
True positive
True positive + fal lse positive
Negative predictive value  =
True negative
True negative + fal lse negativeBMC Pediatrics 2004, 4:13 http://www.biomedcentral.com/1471-2431/4/13
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reason for referral. Ten of these cases were excluded from
analysis because results of the ANA test and titer were not
made available to the rheumatology consultant. Another
18 patients were diagnosed with JRA. We have reported
the presenting signs and symptoms of the majority of
these patients in another paper [7] but include analysis of
the diagnostic utility of the ANA test in those patients
here.
The clinical presentations of 10 patients with SLE were
specifically compared to the 80 patients referred for posi-
tive ANA tests and subsequently shown not to have a
chronic inflammatory disorder. For convenience, these
children will now be referred to as the comparison group.
Presenting complaints of children with SLE and the com-
parison group are shown in Table 1. Children with JRA all
presented with joint swelling and/or gait disturbance as
their chief complaints, as we have previously reported [7].
Diagnoses for the comparison group are shown in Table
2. Of these, the most common diagnoses were hypermo-
bility syndrome and other mechanical musculoskeletal
pain syndromes (n = 39; 49%), consistent with reports
from other pediatric rheumatology centers [13,14]. Viral
arthritis was the next most common diagnosis, seen in 10
patients (13%).
Children with SLE presented with diverse complaints, as
would be expected given the protean nature of the disease.
Most striking was the finding that 4 children with SLE
(40%) and 4 patients in the comparison group (5%) pre-
sented with rash (other than urticaria) as a reason for
seeking medical care. This difference was statistically sig-
nificant (p = 0.0136). All 4 of the SLE patients with rashes
demonstrated prominent facial eruptions in a malar dis-
tribution, while 2 also had non-blanching, purpuric
lesions on the hands and upper and lower extremities.
Three patients in the comparison group also presented
with urticaria; none of the SLE patients presented with
urticarial rash.
Fever, fatigue, and joint swelling were also complaints
seen in both groups. None of these was more significantly
common in one group than in the other by Fisher's exact
test.
Musculoskeletal pain was a symptom for which 3 children
with SLE (30%) were referred, in contrast to the compari-
son group, where musculoskeletal pain was the most
common chief complaint (n = 51, 64%). This difference
was not statistically significant. Thus, children with SLE
differ from children with JRA, who seldom present with
musculoskeletal pain as a primary complaint, as we have
previously reported [7].
Patient age was significantly associated with the likeli-
hood that a patient with a positive ANA test had lupus.
Patients with SLE were significantly older (mean ± sd =
14.2 ± 2.5 years) than the comparison group (11.0 ± 3.6
years; p = 0.007). However, the positive predicative value
for SLE of a positive ANA test in patients 13 years of age or
older was still low (0.17). In contrast, the positive predic-
tive value of a positive ANA test in children under the age
of 13 years was extraordinarily low (0.09).
ANA titers were the best indicator of SLE (Figure 1). While
there was some overlap in ANA titers between the patients
with SLE (1:360–1:10,240) and the comparison group
(1:40–1:640), the median titer between the two groups
(1:1,080 vs. 1:160) was significantly different (p =<
0.0001). All 7 patients with ANA titers ≥1:1,080 had SLE.
Table 1: Presenting complaints of ANA-positive children
Complaint SLE (n = 10) Comparison Group (n = 80)
Musculoskeletal pain 3 (30%) 51 (64%)
Fever 3 (30%) 7 (9%)
Rash (non-urticarial) 4 (40%)* 4 (5%)
Joint swelling 2 (20%) 6 (8%)
Fatigue 2(20%) 4 (5%)
*P = 0.0136
Table 2: Diagnoses of ANA-positive children who did not have 
chronic diflammatory disease (N = 80)
Diagnosis Number




Other mechanical musculoskeletal disorders 22
Viral (transient) arthritis 10
Other 31BMC Pediatrics 2004, 4:13 http://www.biomedcentral.com/1471-2431/4/13
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Thus, the positive predictive value of an ANA titer of
≥1:1,080 for SLE was =1.0. However, there were 9 patients
in the comparison group with ANA titers of 1:640 in
whom history, physical examination, clinical course, and
other supporting laboratory studies excluded SLE. Thus,
the positive predictive value for SLE of an ANA titer of
≥1:640 was 0.42. Low titers were also diagnostically use-
ful. The negative predictive value of a titer of ≤1:360 was
0.84, and of titers ≤1:180 was 1.0.
Seven of the 10 patients referred for a positive ANA test
who were shown to have SLE also had an abnormal CBC.
These included 6 with anemia (hemoglobin <11 g/dL), 4
with leucopenia (white blood cell count <4,000/cu mm)
and one with thrombocytopenia (platelet count
<150,000/cu mm).
Among the patients referred for a positive ANA test, 18, as
noted above, were diagnosed with JRA. ANA titers in JRA
patients ranged between 1:80–1:640 that is, they com-
pletely overlapped the range seen in otherwise healthy
children. Furthermore, the median ANA titer in children
with JRA (1:240) was significantly lower than the ANA
titer seen children with SLE (p = 0.0004). Furthermore, in
the 18 patients with JRA, the ANA test had no diagnostic
utility. That is, the diagnosis of JRA was readily made on
the history of joint swelling and/or gait disturbance and
the physical finding of synovial proliferation [15] at the
time of evaluation in the rheumatology clinic.
Discussion
SLE is a complex, perplexing illness with protean manifes-
tations. While the majority of cases occur in adulthood, as
many as 15–17% of patients present at age 18 years or
younger [2] Thus, pediatricians are likely to encounter this
disease during their careers. Furthermore, because of the
myriad of clinical presentations with which childhood
SLE presents [16,17] it is frequently in the differential
diagnosis of children presenting with challenging or diffi-
cult illnesses. Pediatricians are hampered in making this
diagnosis by the frequency with which positive ANA tests
are encountered in otherwise healthy children. Nonethe-
less, ANA tests continue to be used as a screening proce-
dure to include or exclude rheumatic disease in children
with musculoskeletal complaints. Thus, we sought to
determine whether there are predictable presenting
Scatter plot comparing ANA titers (reciprocal dilution) in children with SLE, JRA, and other disorders Figure 1
Scatter plot comparing ANA titers (reciprocal dilution) in children with SLE, JRA, and other disorders. The median ANA titer 










DilutionBMC Pediatrics 2004, 4:13 http://www.biomedcentral.com/1471-2431/4/13
Page 5 of 6
(page number not for citation purposes)
complaints that would allow the practitioner to distin-
guish children with SLE or JRA from the large number of
children with benign or self-limited illnesses who have
positive ANA tests.
Other studies have verified the lack of specificity of ANA
tests in children. However, each of these previous studies
used a different approach from ours. Both Cabral and col-
leagues [4] and Dean and colleagues [5] examined chil-
dren seen in pediatric rheumatology centers. From their
total patient populations, they selected children with pos-
itive ANA tests and found that as many as 27% had no evi-
dence of a chronic inflammatory disease, even when
followed for periods as long as 7.5 years. Malleson and
colleagues [6] examined records of all children with posi-
tive ANA tests in a large children's hospital and similarly
documented the lack of specificity of the test. Our study is
unique in having started from the practitioners' point of
view. That is, our study focused on children who were
referred because of a positive ANA test and asked whether
there were clinical clues that might have assisted the refer-
ring physician in making or excluding the diagnosis of SLE
prior to referral for subspecialty evaluation. This is a criti-
cal piece of information, since expensive subspecialty care
in many medical environments is subjected to stringent
oversight. Thus, data that assist primary care physicians in
identifying children with the most need for a subspecialty
referral are urgently needed.
We now report that, unlike children with JRA, children
with SLE do not immediately distinguish themselves
based on clinical features. While the diagnosis of SLE may
be straightforward when children present with classic
signs and symptoms of the illness (hematuria, fever,
weight loss, malar rash, and alopecia), our data demon-
strated no single complaint that predicted SLE at presenta-
tion. Musculoskeletal pain, fatigue, and fever were not
seen significantly more frequently in children with SLE
than in children with other illnesses. The sole exception
was the presence of non-urticarial rash, which was more
common in patients with SLE than in the comparison
group. This finding contrasts with our study of children
with JRA, in which affected children were readily distin-
guished from other children with musculoskeletal com-
plaints based on their clinical presentation [7].
Patient age and ANA titer were the best measures distin-
guishing children with SLE from ANA-positive children
with other illnesses or self-limited conditions. While ANA
titers as high as 1:640 can be seen in children who do not
have SLE, in our study, titers of ≥1: 1,080 were highly pre-
dictive of SLE. Similarly, titers of ≤1:360, particularly if
obtained in children under the age of 13 years, safely
excluded SLE.
Although positive ANA tests are sometimes seen in chil-
dren with JRA [18] and juvenile dermatomyositis [19]
positive ANA tests are not distinguishing features of either
of these diseases. As we have previously reported and
demonstrate again here, the history and physical exami-
nation are the critical elements in making the diagnosis of
JRA. Indeed, in this study, ANA tests demonstrated no
ability to discriminate children with JRA from children
presenting with other musculoskeletal complaints. Simi-
larly, the diagnosis of juvenile dermatomyositis is based
on the presence of a characteristic rash and clinical evi-
dence of chronic muscle inflammation [20]. Both of these
can be established without an ANA test. It is also impor-
tant to point out that children with acute lymphocytic
leukemia, a relatively common cause of musculoskeletal
pain in children [21], may also have positive ANA tests
[22].
Because of their limited diagnostic specificity and high
prevalence of false positives, we believe that ANA tests
should be used to address only one clinical question in
pediatrics: does this child have SLE? Titers ≥1:1,080 should
be considered strongly supportive of that diagnosis, while
titers  ≤1:360 make that diagnosis unlikely, particularly
before adolescence. As ever, laboratory findings must be
placed in an appropriate clinical context, and no single
ANA titer should be considered diagnostic of SLE. History,
physical examination, and other supportive laboratory
tests (urinalysis, erythrocyte sedimentation rate or C-reac-
tive protein, serum complement levels, etc. [3]) are
required to establish or exclude a diagnosis of SLE [10].
We conclude that children with SLE are often clinically
indistinguishable from other children with positive ANA
tests in the spectrum of complaints with which they
present for initial medical care. However, judicious use of
the history (presence of morning stiffness), physical
examination (presence of rash), and thoughtful interpre-
tation of ANA titers will significantly assist in
distinguishing children with this life-threatening illness
from children with more benign conditions. ANA tests
have little diagnostic utility in clarifying the diagnosis of
JRA, and should not be used as a screening tool if JRA is
the diagnosis under consideration.
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